These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28375169)

  • 41. Use of 3'-deoxy-3'-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma.
    Lawrence J; Vanderhoek M; Barbee D; Jeraj R; Tumas DB; Vail DM
    Vet Radiol Ultrasound; 2009; 50(6):660-8. PubMed ID: 19999354
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 18F-FDG or 3'-deoxy-3'-18F-fluorothymidine to detect transformation of follicular lymphoma.
    Wondergem MJ; Rizvi SN; Jauw Y; Hoekstra OS; Hoetjes N; van de Ven PM; Boellaard R; Chamuleau ME; Cillessen SA; Regelink JC; Zweegman S; Zijlstra JM
    J Nucl Med; 2015 Feb; 56(2):216-21. PubMed ID: 25593118
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study.
    Mogensen MB; Loft A; Aznar M; Axelsen T; Vainer B; Osterlind K; Kjaer A
    EJNMMI Res; 2017 Dec; 7(1):56. PubMed ID: 28695424
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors.
    Vesselle H; Grierson J; Muzi M; Pugsley JM; Schmidt RA; Rabinowitz P; Peterson LM; Vallières E; Wood DE
    Clin Cancer Res; 2002 Nov; 8(11):3315-23. PubMed ID: 12429617
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study.
    Nguyen NC; Yee MK; Tuchayi AM; Kirkwood JM; Tawbi H; Mountz JM
    Front Oncol; 2018; 8():18. PubMed ID: 29520339
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Role of
    Nak D; Küçük NÖ; Çelebioğlu EC; Bilgiç MS; Hayme S; Kır KM
    Mol Imaging Radionucl Ther; 2022 Oct; 31(3):207-215. PubMed ID: 36268887
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.
    Lee HJ; Oh SJ; Lee EJ; Chung JH; Kim Y; Ryu JS; Kim SY; Lee SJ; Moon DH; Kim TW
    Cancer Chemother Pharmacol; 2015 May; 75(5):1005-13. PubMed ID: 25776904
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine.
    Salskov A; Tammisetti VS; Grierson J; Vesselle H
    Semin Nucl Med; 2007 Nov; 37(6):429-39. PubMed ID: 17920350
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.
    Horn KP; Yap JT; Agarwal N; Morton KA; Kadrmas DJ; Beardmore B; Butterfield RI; Boucher K; Hoffman JM
    Cancer Imaging; 2015 Sep; 15(1):15. PubMed ID: 26335224
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung.
    Sohn HJ; Yang YJ; Ryu JS; Oh SJ; Im KC; Moon DH; Lee DH; Suh C; Lee JS; Kim SW
    Clin Cancer Res; 2008 Nov; 14(22):7423-9. PubMed ID: 19010859
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.
    Chen W; Delaloye S; Silverman DH; Geist C; Czernin J; Sayre J; Satyamurthy N; Pope W; Lai A; Phelps ME; Cloughesy T
    J Clin Oncol; 2007 Oct; 25(30):4714-21. PubMed ID: 17947718
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
    Halter G; Buck AK; Schirrmeister H; Wurziger I; Liewald F; Glatting G; Neumaier B; Sunder-Plassmann L; Reske SN; Hetzel M
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1093-9. PubMed ID: 15052207
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Leimgruber A; Möller A; Everitt SJ; Chabrot M; Ball DL; Solomon B; MacManus M; Hicks RJ
    J Nucl Med; 2014 Jul; 55(7):1075-80. PubMed ID: 24868108
    [TBL] [Abstract][Full Text] [Related]  

  • 55. F-18 fluorodeoxyglucose and F-18 fluorothymidine positron emission tomography/computed tomography imaging in a case of neurosarcoidosis.
    Kim SK; Im HJ; Kim W; Kim TS; Hwangbo B; Kim HJ
    Clin Nucl Med; 2010 Feb; 35(2):67-70. PubMed ID: 20090446
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer.
    Hong YS; Kim HO; Kim KP; Lee JL; Kim HJ; Lee SJ; Lee SJ; Oh SJ; Kim JS; Ryu JS; Moon DH; Kim TW
    J Nucl Med; 2013 Aug; 54(8):1209-16. PubMed ID: 23804324
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical value of 3'-deoxy-3'-[
    Alwadani B; Dall'Angelo S; Fleming IN
    Insights Imaging; 2021 Jul; 12(1):90. PubMed ID: 34213667
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [
    Guglielmo P; Quartuccio N; Rossetti V; Celli M; Alongi P; Boero M; Arnone G; Baldari S; Matteucci F; Laudicella R
    Curr Med Imaging; 2022; 18(4):363-371. PubMed ID: 34533446
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.
    Cheng Z; Wei R; Wu C; Qing H; Jiang X; Lu H; Chen S; Li X; Xu G; Ai H
    Nucl Med Commun; 2015 Sep; 36(9):914-21. PubMed ID: 25973694
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models.
    Apisarnthanarax S; Alauddin MM; Mourtada F; Ariga H; Raju U; Mawlawi O; Han D; Bornmann WG; Ajani JA; Milas L; Gelovani JG; Chao KS
    Clin Cancer Res; 2006 Aug; 12(15):4590-7. PubMed ID: 16899606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.